Journal of Managed Care & Specialty Pharmacy

Article	Citations
Direct medical costs of obesity in the United States and the most populous states	81
Effectiveness of Mobile Applications on Medication Adherence in Adults with Chronic Diseases: A Systematic Review and Meta-Analysis	33
Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine	19
Medication Adherence Trajectories: A Systematic Literature Review	15
COVID-19 and Drug Shortages: A Call to Action	15
Indications for Rituximab Use in an Integrated Health Care Delivery System	12
Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study	12
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States	12
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis	12
Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy	11
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis	10
Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database	10
Effect of Headache-Free Days on Disability, Productivity, Quality of Life, and Costs Among Individuals with Migraine	10
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies	10
Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy	10
Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease	10
Effect of Pharmacist-Driven Professional Continuous Glucose Monitoring in Adults with Uncontrolled Diabetes	10
Burden of hospitalization for heart failure in the United States: a systematic literature review	10
AMCP Partnership Forum: Digital Therapeutics—What Are They and Where Do They Fit in Pharmacy and Medical Benefits?	10
Direct health care costs associated with COVID-19 in the United States	10
Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population	9
Validation of EHR medication fill data obtained through electronic linkage with pharmacies	9
Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States	9
Racial disparities in medication use: imperatives for managed care pharmacy	9
Economic value of nonsurgical weight loss in adults with obesity	9

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients	9
Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis	9
Procurement and use of social determinants of health data among key health care stakeholders	8
Integrating E-Prescribing and Pharmacy Claims Data for Predictive Modeling: Comparing Costs and Utilization of Health Plan Members Who Fill Their Initial Medications with Those Who Do Not	8
All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States	8
The effectiveness and value of aducanumab for Alzheimer’s disease	8
Polypharmacy Among Privately Insured Adults with Cerebral Palsy: A Retrospective Cohort Study	8
Evaluation of a Pharmacist-Managed Nonsteroidal Anti-Inflammatory Drugs Deprescribing Program in an Integrated Health Care System	8
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A	8
Use of real-world evidence in economic assessments of pharmaceuticals in the United States	7
Polypharmacy is a risk factor for mortality, severe chronic kidney disease, and liver disease among privately insured adults with cerebral palsy	7
Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data	7
Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes	7
Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries	7
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs	7
Impact of financial medication assistance on medication adherence: a systematic review	7
Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb	7
Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation	7
Assessing the Population-Level Correlation of Medication Regimen Complexity and Adherence Indices Using Electronic Health Records and Insurance Claims	7
Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy	7
Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products	7
Drugs likely subject to Medicare negotiation, 2026-2028	7
Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital’s Perspective	6
Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications	6
Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database	6
Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018	6
Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review	6
Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure	6
Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder	6
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease	6
The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States	6
Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States	6
Payer perceptions of the use of real-world evidence in oncology-based decision making	6
Economic burden of peanut allergy in pediatric patients with evidence of reactions to peanuts in the United States	6
Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary	6
Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system	6
The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer	6
Improving patient-reported measures in oncology: a payer call to action	6
Pharmacists as accessible health care providers: quantifying the opportunity	6
Statin use and mortality in rheumatoid arthritis: an incident user cohort study	6
Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis	6
Economic burden of growth hormone deficiency in a US pediatric population	5
Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment	5
Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression	5
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015	5
The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database	5
The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study	5
Decision makers need an approach to determine digital therapeutic product quality, access, and appropriate use	5
Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities	5
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population	5

Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients	5
Effect of clinical pharmacist interventions on cost in an integrated health system specialty pharmacy	5
Patient Medication Adherence Among Pharmacies Participating in a North Carolina Enhanced Services Network	5
Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare s	5
Medication Therapy Management: 10 Years of Experience in a Large Integrated Health Care System	5
The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy	5
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer	5
Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use	5
One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults	5
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions	5
Healthcare resource utilization and cost among patients with type 1 diabetes in the United States	5
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma	5
Trends in off-label use of antipsychotic medications among Texas Medicaid children and adolescents from 2013 to 2016	5
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology	5
Benefits of Prior Authorizations	5
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States	5
Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis	5
Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer	5
The effectiveness and value of novel acute treatments for migraine	4
Association of Medication Adherence with Hospital Utilization and Costs Among Elderly with Diabetes Enrolled in a State Pharmaceutical Assistance Program	4
Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospectiv	4
Burden of illness among patients with dementia-related psychosis	4
Implementation and Effect of a Pharmacist-to-Pharmacist Transitions of Care Initiative on Ambulatory Care Sensitive Conditions	4
Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting	4
Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States	4
Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care	4
Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States	4
Performance-based pharmacy payment models: key components and critical implementation considerations for successful uptake and integration	4
Cost of epilepsy-related health care encounters in the United States	4
The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD	4
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis	4
The economic burden of Parkinson disease among Medicare beneficiaries	4
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States	4
Estimated discounts generated by Medicare drug negotiation in 2026	4
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system	4
Pharmacy’s Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging	4
Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis	4
Association between multiple sclerosis disease severity and adherence to disease-modifying therapies	4
Social determinants of health and adult influenza vaccination: a nationwide claims analysis	4
Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study	4
The direct and indirect costs of adult atopic dermatitis	4
Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis	4
Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims	4
Need for payer-provider partnerships in addressing social determinants of health	4
Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States	4
Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control	4
AMCP Pay-for-Performance Principles: Performance-Based Reimbursement and Direct and Indirect Remuneration (DIR) Fees	4
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis	4
Evaluation of a Pharmacist-Led Intervention to Improve Statin Use in Persons with Diabetes	4
Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data	4
Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review	4
HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales	4
Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States	4
Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis	4
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective	3
Specialty drug and health care utilization vary by wage level in employer-sponsored health plans	3
Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatme	3
Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study	3
International reference pricing for prescription drugs: a landscape analysis	3
Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States	3
Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer	3
Association of 3 CDC opioid prescription guidelines for chronic pain and 2 payer pharmacy coverage changes on opioid initiation practices	3
Proposal for capturing patient experience through extended value frameworks of health technologies	3
The effectiveness and value of novel treatments for cystic fibrosis	3
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations	3
Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study	3
Few new drugs deserve expedited regulatory treatment	3
The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease	3
Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?	3
A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA’s Sentinel Initiative	3
COVID-19 vaccination and race – A nationwide survey of vaccination status, intentions, and trust in the US general population	3
Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative	3
A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States	3
Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis	3
Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States	3
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support	3
Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis	3
Self-reported adherence and reasons for nonadherence among patients with low proportion of days covered for antihypertension medications	3
Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers	3
Real-world analysis of insurance churn among young adults with schizophrenia using the Colorado All-Payer Claims Database	3

Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration	3
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value	3
The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov	3
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease	3
The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population	3
Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy	3
Mavacamten for hypertrophic cardiomyopathy: effectiveness and value	3
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports	3
Association of dyskalemias with short-term health care utilization in patients with advanced CKD	3
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations	3
A Physician’s Perspective on Generic Drug Quality	3
Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies	3
The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective	3
Assessment of Clinically Relevant Drug Interactions by Online Programs in Renal Transplant Recipients	3
Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States	3
Health care costs and utilization prior to diagnosis of antineutrophil cytoplasmic antibody vasculitis in Medicare beneficiaries	2
Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate	2
Trends in add-on medications following metformin monotherapy for type 2 diabetes	2
Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population	2
Evaluating perceptions of social determinants of health and Part D star performance of Medicare Advantage-contracted primary care providers serving a South Texas market	2
Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy	2
Navigating changes in Clostridioides difficile prevention and treatment	2
A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis	2
Clinical and economic impact of primary hyperoxaluria: a retrospective claims analysis	2
Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials	2
Methodology for conducting a comprehensive product review in managed care	2
A primer on managed care pharmacy	2
Cardiorenal disease in the United States: Future health care burden and potential impact of novel therapies	2
Evaluation of a pharmacist-driven medication adherence enhancement service	2
Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspectiv	2
Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma	2
The cost impact of disease progression to metastatic castration-sensitive prostate cancer	2
Use of prescriber requirements among US commercial health plans	2
A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?	2
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia	2
The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Ad	2
COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data	2
The role of integrated medical and prescription drug plans in addressing racial and ethnic disparities in medication adherence	2
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	2
Top Evidentiary Gaps in Managed Care Pharmacy: A Research Agenda	2
The patient’s medication access journey: a conceptual framework focused beyond adherence	2
The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis	2
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective	2
Poster Abstracts - Academy of Managed Care Pharmacy 2023	2
Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida’s Acute Pain Opioid Restriction Law	2
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 3	2
Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database	2
Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements	2
Cost sharing: implications of a well-intended benefits strategy	2
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders	2
Meeting Abstracts - AMCP 2020	2
Racial and ethnic disparities due to Medicare Part D Star Ratings criteria among kidney transplant patients with diabetes, hypertension, and/or dyslipidemia	2
Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation	2
Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study	2
Effect of the ExactCare medication care management model on adherence, health care utilization, and costs	2
Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States	2
Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs	2
The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018	2
Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers	2
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis	2
Health care costs and resource use of managing hemophilia A: A targeted literature review	2
Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrosp	2
Qualitative exploration of factors influencing the plan selection process by Medicare beneficiaries	2
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	2
Distinguishing Predatory from Reputable Publishing Practices	2
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	2
Design and effect of performance-based pharmacy payment models	2
Insurance Denials of Care Amount to Unlicensed Medical Practice	2
Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes	2
Annual costs among patients with major depressive disorder and the impact of key clinical events	2
Development and Implementation of Clinical Outcome Measures for Automated Collection Within Specialty Pharmacy Practice	2
Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage	2
The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease	2
Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model	2
Correction	2
Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective	2
Oral treatments for outpatient COVID-19: Effectiveness and value	2
Is the Quality of Generic Drugs Cause for Concern?	2
The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy	2
What Was, Is No More: Community Pharmacy Economics	2
Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility	2
The impact of biosimilar insulins on the diabetes landscape	2
US health care utilization and costs in adult patients with atopic dermatitis by disease severity	2
A prediction model for nonpersistence or nonadherence to direct oral anticoagulants in hospitalized patients with atrial fibrillation	2
Association between health system specialty pharmacy use and health care costs among national sample of Medicare Advantage beneficiaries	2
Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis	2
Can We Trust the Quality of Generic Drugs?	2
Evaluating Success Factors of a Medication Adherence Tracker Pilot Program in Improving Part D Medication Adherence Metrics in a Medicare Advantage Plan: Importance of Provider Engagement	2
Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration–approved solid tumor therapies, 1995-2021	2
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	2
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model	2
Pitfalls of Cost-Effectiveness Analysis in Practice: A TRD Case Example in the United States with Esketamine Versus Oral Antidepressants	2
Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases	2
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars	2
Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis	2